These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 7863437)
1. [The use of acarbose for treating diabetic patients]. Balabolkin MI; Dedov II; Mkrtumian AM; Ametov AS; Kakhnovskiĭ IM; Chazova TE; Koroleva TS; Kochergina II; Matveeva LS Ter Arkh; 1994; 66(10):20-1. PubMed ID: 7863437 [No Abstract] [Full Text] [Related]
2. Acarbose: in search for its real indications in current medical practice. Lerman I; Gómez Perez FJ; Aguilar-Salinas CA; Rodrigo JA Diabetes Care; 1996 Jan; 19(1):94-5. PubMed ID: 8720547 [No Abstract] [Full Text] [Related]
3. Acarbose in the treatment of type I diabetes. Hollander P; Pi-Sunyer X; Coniff RF Diabetes Care; 1997 Mar; 20(3):248-53. PubMed ID: 9051366 [TBL] [Abstract][Full Text] [Related]
4. New horizons in diabetes therapy--alpha glucosidase inhibitors. Jawad F J Pak Med Assoc; 1994 Mar; 44(3):59-60. PubMed ID: 8040998 [No Abstract] [Full Text] [Related]
5. [Efficacy and safety of acarbose treatment of NIDDM]. Wainstein J; Jedwab M Harefuah; 1997 Feb; 132(4):258-63, 311. PubMed ID: 9153894 [TBL] [Abstract][Full Text] [Related]
6. The use of acarbose in the prevention and treatment of hypoglycaemia. Lefebvre PJ; Scheen AJ Eur J Clin Invest; 1994 Aug; 24 Suppl 3():40-4. PubMed ID: 8001627 [TBL] [Abstract][Full Text] [Related]
7. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Spengler M; Cagatay M Clin Invest Med; 1995 Aug; 18(4):325-31. PubMed ID: 8549020 [TBL] [Abstract][Full Text] [Related]
8. [Improvement in diabetes therapy. Interview by Heike E. Nähtke]. Mehnert H Fortschr Med; 1990 Sep; 108(27):72, 75. PubMed ID: 2227754 [No Abstract] [Full Text] [Related]
9. [The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance]. Gendeleka GF Lik Sprava; 1997; (6):105-7. PubMed ID: 9589946 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Hoffmann J; Spengler M Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525 [TBL] [Abstract][Full Text] [Related]
11. Acarbose and insulin therapy in type I diabetes mellitus. Rios MS Eur J Clin Invest; 1994 Aug; 24 Suppl 3():36-9. PubMed ID: 8001626 [TBL] [Abstract][Full Text] [Related]
12. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508 [TBL] [Abstract][Full Text] [Related]
17. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose. Scott RS; Knowles RL; Beaven DW Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178 [TBL] [Abstract][Full Text] [Related]
18. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Costa B; Piñol C Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244 [TBL] [Abstract][Full Text] [Related]
19. [New, in Austria registered specialty drugs. Glucobay (acarbose)]. Sturm M Wien Klin Wochenschr; 1992; 104(11):329-36. PubMed ID: 1621396 [No Abstract] [Full Text] [Related]
20. [Role of acarbose in the treatment of diabetes mellitus]. Scheen AJ Diabetes Metab; 1998 Sep; 24(4):385-90. PubMed ID: 9805654 [No Abstract] [Full Text] [Related] [Next] [New Search]